Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
October 28, 2020Targovax announces formation of new Scientific Advisory Board
-
October 26, 2020Targovax ASA: Invitation to presentation of Targovax’s third quarter 2020 results, Thursday 5 November
-
October 22, 2020TARGOVAX ASA – REGISTRATION OF SHARE CAPITAL INCREASE FOLLOWING THE PRIVATE PLACEMENT
-
October 20, 2020TARGOVAX ASA – NO SUBSEQUENT OFFERING
Third quarter 2020
Targovax ASA (OSE: TRVX) will announce its third quarter 2020 results on Thursday 5 November 2020.